Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BREZ NASDAQ:CLNN NASDAQ:LOAC NASDAQ:ROCC NASDAQ:TOTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBREZBreeze Holdings Acquisition$11.43$10.38▼$12.24$48.98M0.03N/AN/ACLNNClene$3.77+1.9%$3.56$2.28▼$6.96$30.59M0.5589,123 shs18,586 shsLOACLongevity Acquisition$13.45$12.99$10.24▼$19.25$35.32M-0.0192,113 shs47,631 shsROCCRoth CH Acquisition II$37.47$9.01$8.78▼$11.58$1.56B2.65477,953 shsN/ATOTATottenham Acquisition I$10.82$10.97$10.30▼$17.50$37.39M0.0536,696 shsN/AElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBREZBreeze Holdings Acquisition0.00%0.00%0.00%0.00%0.00%CLNNClene+1.89%-1.57%-14.71%+25.67%-23.06%LOACLongevity Acquisition0.00%0.00%0.00%0.00%0.00%ROCCRoth CH Acquisition II0.00%0.00%0.00%0.00%0.00%TOTATottenham Acquisition I0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBREZBreeze Holdings AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACLNNClene3.5729 of 5 stars3.65.00.00.02.72.50.6LOACLongevity AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AROCCRoth CH Acquisition IIN/AN/AN/AN/AN/AN/AN/AN/ATOTATottenham Acquisition IN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBREZBreeze Holdings Acquisition 0.00N/AN/AN/ACLNNClene 3.17Buy$40.00961.01% UpsideLOACLongevity Acquisition 0.00N/AN/AN/AROCCRoth CH Acquisition II 0.00N/AN/AN/ATOTATottenham Acquisition I 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TOTA, ROCC, BREZ, LOAC, and CLNN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.005/8/2025CLNNCleneBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$84.00 ➝ $33.005/8/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.004/23/2025CLNNCleneJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBREZBreeze Holdings AcquisitionN/AN/AN/AN/A($2.25) per shareN/ACLNNClene$350K89.05N/AN/A($1.06) per share-3.56LOACLongevity AcquisitionN/AN/AN/AN/A$0.92 per shareN/AROCCRoth CH Acquisition II$1.15B1.36$16.51 per share2.27$25.40 per share1.48TOTATottenham Acquisition IN/AN/AN/AN/A$7.63 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBREZBreeze Holdings Acquisition-$2.55MN/A0.00N/AN/AN/AN/A-181.15%N/ACLNNClene-$39.40M-$4.04N/AN/AN/A-8,306.00%N/A-105.11%8/6/2025 (Estimated)LOACLongevity Acquisition-$290KN/AN/A∞N/AN/A-10.12%-1.43%N/AROCCRoth CH Acquisition II$217.69M$13.822.713.65N/A24.39%43.26%21.78%N/ATOTATottenham Acquisition I$270KN/AN/A∞N/AN/A-1.14%-1.05%N/ALatest TOTA, ROCC, BREZ, LOAC, and CLNN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025CLNNClene-$0.49N/AN/AN/A$0.06 millionN/A5/7/2025Q1 2025CLNNClene-$1.10-$0.50+$0.60-$0.09$0.07 million$0.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBREZBreeze Holdings AcquisitionN/AN/AN/AN/AN/ACLNNCleneN/AN/AN/AN/AN/ALOACLongevity AcquisitionN/AN/AN/AN/AN/AROCCRoth CH Acquisition IIN/AN/AN/AN/AN/ATOTATottenham Acquisition IN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBREZBreeze Holdings AcquisitionN/A0.030.03CLNNCleneN/A1.361.36LOACLongevity Acquisition0.360.100.10ROCCRoth CH Acquisition II0.540.710.71TOTATottenham Acquisition IN/A0.120.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBREZBreeze Holdings Acquisition22.33%CLNNClene23.28%LOACLongevity Acquisition51.38%ROCCRoth CH Acquisition II95.77%TOTATottenham Acquisition I53.05%Insider OwnershipCompanyInsider OwnershipBREZBreeze Holdings Acquisition59.30%CLNNClene35.30%LOACLongevity Acquisition47.60%ROCCRoth CH Acquisition II51.79%TOTATottenham Acquisition I2.26%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBREZBreeze Holdings Acquisition44.30 million1.75 millionNot OptionableCLNNClene1008.27 million5.35 millionOptionableLOACLongevity AcquisitionN/A2.63 millionN/ANot OptionableROCCRoth CH Acquisition IIN/A41.56 million20.04 millionNot OptionableTOTATottenham Acquisition IN/A3.46 millionN/ANot OptionableTOTA, ROCC, BREZ, LOAC, and CLNN HeadlinesRecent News About These CompaniesTottenham hierarchy ‘dreaming’ of signing ‘exceptional’ 19-G/A star who will cost £67mMay 22, 2025 | msn.comTottenham given green light to sign former Man Utd star after major transfer announcementMay 20, 2025 | msn.comReport: Tottenham set asking price for 13-G/A star amid interest from Premier League rivalsMay 12, 2025 | msn.comOne in one out: Tottenham ‘most interested’ in 27-year-old England ace, could swap him with first-team starApril 30, 2025 | msn.comTottenham pursuing 17-G/A star since last year, rivals could scupper transfer plansApril 19, 2025 | msn.comBoost for Tottenham as 'extraordinary' January target made available on a bargainApril 10, 2025 | msn.comTottenham have advantage in the race to sign 23-year-old, club open to Spurs saleApril 2, 2025 | msn.comTottenham takeover: Qatar could agree ‘amazing’ deal – Stefan BorsonFebruary 19, 2025 | footballinsider247.comFTottenham Hotspur Pushing to Sign £27m Serie A Midfielder in January Move – ReportJanuary 12, 2025 | sports.yahoo.comTTLB Opinion- Cut-price deal for Southampton star can help salvage Tottenham’s 2024-25 campaignJanuary 8, 2025 | msn.comTottenham have ‘asked for information’ about player yet to start a game this seasonJanuary 3, 2025 | msn.comTottenham eyeing January move for PL star with ‘absolutely sensational’ football IQDecember 20, 2024 | msn.comJohan Lange to lead negotiations for Tottenham January target who will cost over £50mDecember 12, 2024 | msn.comStriker with 72 goals & 23 assists tipped for Tottenham move in incredible swap deal involving RicharlisonDecember 8, 2024 | msn.comReport: 'Nothing' to Rumors of Cowboys' Jerry Jones Buying EPL's Tottenham HotspurDecember 4, 2024 | bleacherreport.comBTottenham looking to bring 28-year-old back to England, would require a considerable feeDecember 3, 2024 | msn.comTottenham keen on 56-Premier League goal player in potential free transferDecember 3, 2024 | msn.comI only signed for Tottenham because I was forced out of NewcastleNovember 19, 2024 | metro.co.ukMReport: Tottenham Join Race for Brighton’s Versatile Full-BackNovember 16, 2024 | sports.yahoo.comWhy do Tottenham keep conceding the first goal in their Premier League matches?November 15, 2024 | nytimes.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTOTA, ROCC, BREZ, LOAC, and CLNN Company DescriptionsBreeze Holdings Acquisition NASDAQ:BREZBreeze Holdings Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on businesses in the defense technology industry. The company was incorporated in 2020 and is based in Irving, Texas. Breeze Holdings Acquisition Corp operates as a subsidiary of Breeze Sponsor, LLC.Clene NASDAQ:CLNN$3.77 +0.07 (+1.89%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$3.75 -0.02 (-0.53%) As of 07/16/2025 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Longevity Acquisition NASDAQ:LOACLongevity Acquisition Corporation does not have significant operations. The company focuses on acquiring, engaging in a share exchange, share reconstruction and amalgamation, purchasing of assets, entering into contractual arrangements, or other business combination with one or more businesses. Longevity Acquisition Corporation was founded in 2018 and is based in Shanghai, the People's Republic of China.Roth CH Acquisition II NASDAQ:ROCCRoth CH Acquisition II Co. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. The company was formerly known as Roth Acquisition I Co. Roth CH Acquisition II Co. was incorporated in 2019 and is based in Newport Beach, California.Tottenham Acquisition I NASDAQ:TOTATottenham Acquisition I Limited does not have significant operations. The company intends to enter into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. It focuses on the technology, media, telecom, education, e-commerce, health-care, and consumer goods industries with primary operations in Asia. The company was founded in 2017 and is based in Central, Hong Kong. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
